Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 24 Sept 2010 |
| Orion: Change in the holding of own shares | 1 Sept 2010 |
| Orion comments on today's FDA release on safety review of Stalevo® | 20 Aug 2010 |
| SHARE ACQUISITIONS 18/08/2010 | 18 Aug 2010 |
| SHARE ACQUISITIONS 17/08/2010 | 17 Aug 2010 |